| Personalized tuberculosis treatment through model-informed dosing of rifampicin SW van Beek, R Ter Heine, RJ Keizer, C Magis-Escurra, RE Aarnoutse, ... Clinical pharmacokinetics 58, 815-826, 2019 | 32 | 2019 |
| Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase … SC van der Boor, MJ Smit, SW van Beek, J Ramjith, K Teelen, ... The Lancet Infectious Diseases 22 (11), 1596-1605, 2022 | 23 | 2022 |
| Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant tuberculosis P Ngwalero, JCM Brust, SW van Beek, S Wasserman, G Maartens, ... Antimicrobial agents and chemotherapy 65 (11), 10.1128/aac. 02399-20, 2021 | 14 | 2021 |
| A model-informed method for the purpose of precision dosing of isoniazid in pulmonary tuberculosis SW van Beek, R Ter Heine, JWC Alffenaar, C Magis-Escurra, ... Clinical Pharmacokinetics 60, 943-953, 2021 | 11 | 2021 |
| Pharmacogenetics of between-individual variability in plasma clearance of bedaquiline and clofazimine in South Africa DW Haas, MT Abdelwahab, SW van Beek, P Baker, G Maartens, ... The Journal of infectious diseases 226 (1), 147-156, 2022 | 10 | 2022 |
| A new framework to implement model-informed dosing in clinical guidelines: piperacillin and amikacin as proof of concept SJF Hartman, JGE Swaving, SW Van Beek, BD Van Groen, M De Hoop, ... Frontiers in Pharmacology 11, 592204, 2020 | 10 | 2020 |
| Pharmacokinetically‐guided dosing to improve the efficacy of brigatinib in non‐small cell lung cancer patients SE Koele, SW van Beek, AJ van der Wekken, B Piet, MM van den Heuvel, ... British journal of clinical pharmacology 88 (4), 1930-1934, 2022 | 3 | 2022 |
| Safety, Tolerability and Plasmodium Falciparum Transmission-Reducing Activity of Monoclonal Antibody TB31F: An Open-Label, First-in-Human, Trial in Healthy … SC van der Boor, M Smit, SW van Beek, J Ramjith, K Teelen, ... | 3 | 2022 |
| First-in-Human Evaluation of a Plasmodium falciparum Transmission-Blocking Monoclonal Antibody SC van der Boor, MJ Smit, SW van Beek, J Ramjith, P Pickkers, Y Wu, ... AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE 105 (5), 204-205, 2021 | 2 | 2021 |
| Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis R Stemkens, V Jager, R Dawson, AH Diacon, K Narunsky, ... Antimicrobial Agents and Chemotherapy 67 (10), e00683-23, 2023 | 1 | 2023 |
| Modeling the Impact of a Highly Potent Plasmodium falciparum Transmission-Blocking Monoclonal Antibody in Areas of Seasonal Malaria Transmission JD Challenger, SW Van Beek, R Ter Heine, SC Van Der Boor, ... The Journal of Infectious Diseases 228 (2), 212-223, 2023 | 1 | 2023 |
| Combatting seasonal malaria transmission using a highly potent Plasmodium falciparum transmission-blocking monoclonal antibody JD Challenger, SW van Beek, R Heine, SC van der Boor, GD Charles, ... medRxiv, 2022.09. 11.22279612, 2022 | 1 | 2022 |
| Model-predicted impact of ECG monitoring strategies during bedaquiline treatment SW Van Beek, L Tanneau, G Meintjes, S Wasserman, NR Gandhi, ... Open Forum Infectious Diseases 9 (8), ofac372, 2022 | 1 | 2022 |
| Optimized Loading Dose Strategies for Bedaquiline When Restarting Interrupted Drug-Resistant Tuberculosis Treatment SE Koele, SW Van Beek, G Maartens, JCM Brust, EM Svensson Antimicrobial agents and chemotherapy 66 (3), e01749-21, 2022 | 1 | 2022 |
| Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa SW van Beek, EM Svensson, AB Tiono, J Okebe, U D’Alessandro, ... Parasites & vectors 14, 1-11, 2021 | 1 | 2021 |
| THE PUBLIC HEALTH IMPACT OF A HIGHLY POTENT PLASMODIUM FALCIPARUM TRANSMISSION-BLOCKING MONOCLONAL ANTIBODY IN SETTINGS WITH SEASONAL MALARIA TRANSMISSION JD Challenger, SW van Beek, R ter Heine, SC van der Boor, GD Charles, ... Model-informed pharmacological interventions against tuberculosis and …, 2022 | | 2022 |
| Model-informed pharmacological interventions against tuberculosis and malaria SW van Beek | | 2022 |
| P0516/# 1936: A NEW FRAMEWORK TO IMPLEMENT MODEL-INFORMED DOSING IN CLINICAL GUIDELINES: PIPERACILLIN AND AMIKACIN AS PROOF OF CONCEPT S Hartman, J Swaving, S Van Beek, B Van Groen, M De Hoop, ... Pediatric Critical Care Medicine 22 (Supplement 1 3S), 259, 2021 | | 2021 |
| 858: A New Framework to Implement Model-Informed Dosing in Clinical Guidelines: A Proof-of-Concept Study S Hartman, J Swaving, S Van Beek, B Van Groen, M De Hoop, ... Critical Care Medicine 49 (1), 426, 2021 | | 2021 |
| Quantifying the effects of hepatic impairment on abemaciclib exposure to support dosing recommendations SW van Beek, PK Turner, JS Van der Walt EUROPEAN JOURNAL OF CANCER 103, E126-E126, 2018 | | 2018 |
